Retatrutide — Research Overview
Chemical Name: LY3437943 Also Known As: Retatrutide Developer: Eli Lilly and Company Structure: 39-amino acid peptide linked to a C20 fatty diacid moiety Targets: GLP-1 receptor, GIP receptor, and glucagon receptor simultaneously Category: Triple hormone receptor agonist / incretin-based research peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Retatrutide?
Retatrutide is a synthetic single-peptide compound engineered to simultaneously activate three hormone receptors — the glucagon-like peptide 1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This makes it the first triple hormone receptor agonist to reach published Phase 2 clinical trial data in humans, and the most clinically advanced compound of its class in the research literature as of 2024.
Each of the three receptors targeted by retatrutide plays a distinct role in metabolic regulation. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation amplifies insulin secretion in a glucose-dependent manner and contributes to improved lipid metabolism. Glucagon receptor activation increases energy expenditure and stimulates hepatic fatty acid oxidation, adding a thermogenic dimension that single and dual agonists do not provide.
Retatrutide was designed with a deliberate receptor potency balance — it is more potent at the human GIP receptor than native GIP, and less potent at the GLP-1 and glucagon receptors than their respective native hormones. This balance was intended to maximize metabolic efficacy while minimizing adverse effects associated with supraphysiological glucagon activity. Its C20 fatty diacid moiety extends the pharmacokinetic half-life, enabling once-weekly subcutaneous dosing in clinical trial protocols.
Mechanism of Action
Retatrutide acts simultaneously across three distinct G-protein-coupled receptor pathways that collectively regulate energy intake, energy expenditure, glucose homeostasis, lipid metabolism, and hepatic fat storage.
GLP-1 receptor agonism reduces caloric intake by acting on hypothalamic appetite centers and slowing gastric emptying, producing earlier and more sustained satiety signals. This is the same receptor targeted by semaglutide and a component of the mechanism of tirzepatide.
GIP receptor agonism amplifies insulin secretion in a glucose-dependent manner, meaning it enhances insulin release when blood glucose is elevated without driving hypoglycemia when glucose is normal. GIP agonism also contributes to favorable shifts in lipid metabolism and has been associated in research with reduced nausea compared to GLP-1 agonism alone.
Glucagon receptor agonism increases hepatic energy expenditure by stimulating fatty acid oxidation in the liver, reducing hepatic lipogenesis, and increasing circulating levels of beta-hydroxybutyrate — a biomarker of active fatty acid oxidation. This is the mechanism responsible for retatrutide’s notably greater liver fat reduction compared to GLP-1 or dual GLP-1/GIP agonists in published research. Glucagon receptor agonism also appears to influence PCSK9 degradation, which may explain the reductions in LDL cholesterol observed in clinical data.
The combination of reduced energy intake through GLP-1 and GIP signaling, alongside increased energy expenditure through glucagon receptor activation, is the central rationale for retatrutide’s development as a next-generation compound beyond existing approved metabolic agents.
Published Research
Study 1 — Phase 2 Clinical Trial: Obesity Without Type 2 Diabetes
Authors: Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Year: 2023 Journal: New England Journal of Medicine Full text: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
This is the landmark Phase 2 clinical trial of retatrutide in adults with obesity but without type 2 diabetes. It was a double-blind, randomized, placebo-controlled trial enrolling adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition. Participants were randomized to receive once-weekly subcutaneous injections of retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks. Key findings from this trial:
At the highest dose of 12 mg, participants experienced a mean body weight reduction of 24.2% from baseline at 48 weeks, compared to 2.1% in the placebo group. This represented the largest weight reduction ever reported in a Phase 2 obesity pharmacotherapy trial at the time of publication.
Weight reductions were accompanied by improvements across multiple cardiometabolic measures including waist circumference, systolic and diastolic blood pressure, glycated hemoglobin, fasting glucose, insulin levels, and lipid profiles. LDL cholesterol was reduced by approximately 20% in treated participants.
72% of participants who had prediabetes at baseline reverted to normoglycemia during retatrutide treatment.
The safety profile was consistent with known GLP-1 and GIP/GLP-1 based therapies. The most frequently reported adverse events were transient, mostly mild to moderate gastrointestinal effects including nausea, vomiting, and diarrhea, occurring primarily during the dose escalation period. These events were more frequent in the 8 mg and 12 mg groups and were more common when starting at a 4 mg initial dose compared to a 2 mg initial dose, informing subsequent dose escalation protocol design.
Study 2 — Phase 2 Clinical Trial: Type 2 Diabetes
Authors: Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Year: 2023 Journal: The Lancet PMID: 37385280 Full text: https://pubmed.ncbi.nlm.nih.gov/37385280/
This Phase 2 randomized, double-blind, placebo-controlled and active comparator-controlled trial examined retatrutide in adults with type 2 diabetes and overweight or obesity across 42 research and healthcare centers in the United States. Participants received once-weekly injections of retatrutide at maintenance doses of 0.5 mg, 4 mg, 8 mg, or 12 mg, or placebo, or 1.5 mg dulaglutide as an active comparator, over 36 weeks. Key findings:
Retatrutide produced clinically meaningful reductions in HbA1c across all doses tested. At the 12 mg dose HbA1c was reduced by 2.2 percentage points from baseline.
Between 77% and 82% of participants on retatrutide achieved euglycemia defined as HbA1c of 6.5% or lower by week 36, compared to significantly lower rates in the dulaglutide and placebo groups.
Between 57% and 63% of retatrutide-treated participants with type 2 diabetes achieved body weight reductions of 15% or greater, with a mean weight loss of 16.9% at the highest dose at 36 weeks.
Results were superior to the active comparator dulaglutide 1.5 mg on both glycemic and body weight endpoints.
The safety profile was consistent with GLP-1 receptor agonists and GIP/GLP-1 receptor agonists. The authors concluded these Phase 2 data informed dose selection for the Phase 3 program.
Study 3 — Phase 2a Clinical Trial: Metabolic Dysfunction-Associated Steatotic Liver Disease
Year: 2024 Journal: Nature Medicine Full text: https://www.nature.com/articles/s41591-024-03018-2 PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
This Phase 2a randomized clinical trial examined retatrutide specifically in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease — a condition affecting an estimated 38% of the global population as of recent epidemiological data and for which no approved pharmacological treatments currently exist in the United States or Europe. Key findings:
Retatrutide produced up to 82% reduction in liver fat from baseline in treated participants, representing one of the largest reductions in hepatic steatosis reported in a pharmacological trial of this type.
Levels of beta-hydroxybutyrate — a biomarker of hepatic fatty acid oxidation — increased two to threefold in a dose-related pattern with retatrutide at doses of 4 mg and higher, and changes in beta-hydroxybutyrate were significantly correlated with reductions in liver fat. This finding supports the hypothesis that glucagon receptor agonism contributes directly to liver fat reduction beyond what is explained by weight loss alone.
The authors noted that the additional liver fat lowering observed with retatrutide compared to GLP-1 mono-agonists and tirzepatide may reflect direct hepatic effects of glucagon receptor agonism, including stimulation of hepatic fatty acid oxidation and reduction of hepatic lipogenesis, in addition to the greater overall weight reduction achieved with triple agonism.
Study 4 — Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Published in PMC Year: 2024 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
This systematic review and meta-analysis searched PubMed, Scopus, Web of Science, and Cochrane databases and identified three randomized controlled trials encompassing 878 participants that met inclusion criteria. Key pooled findings across the analyzed trials:
Retatrutide significantly reduced body weight with a mean difference of 14.33% across analyzed doses and timepoints.
BMI was reduced by a mean of 5.38 points and waist circumference by a mean of 10.51 centimeters.
Fasting plasma glucose was reduced by a mean of 23.51 mg/dL and HbA1c by a mean of 0.91 percentage points.
The authors concluded retatrutide has potential to be a highly effective pharmacological option for clinically meaningful weight reduction in individuals with obesity, and noted the findings may warrant reassessment of conventional 5% weight reduction targets used in obesity treatment research.
Gastrointestinal adverse events including nausea, diarrhea, vomiting, and constipation were more common in retatrutide groups than placebo, particularly at higher doses, though rates of treatment discontinuation due to adverse events remained relatively low.
Study 5 — Triple Agonism Based Therapies for Obesity: Comprehensive Clinical Review
Authors: Papamargaritis D, Davies MJ, et al. Journal: PMC Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/
This peer-reviewed review summarizes the scientific rationale and clinical trial evidence for triple receptor agonism in obesity and type 2 diabetes research, with retatrutide as the primary subject. The authors describe retatrutide as the first triple agonist with published Phase 2 data in both obesity and type 2 diabetes populations. Key points from this review:
Retatrutide achieved up to 24.2% mean weight loss at 48 weeks in individuals with obesity and 16.9% at 36 weeks in individuals with type 2 diabetes — results that exceed published outcomes from semaglutide and approach or exceed those of tirzepatide in comparable timeframes.
In the type 2 diabetes Phase 2 trial, 82% of participants reached HbA1c of 6.5% or lower and 63% achieved body weight reductions of 15% or greater, representing performance superior to dulaglutide as the active comparator.
The review places retatrutide within the broader context of incretin-based therapy development, noting that incorporating glucagon receptor agonism into GLP-1 and GIP based compounds may enhance efficacy through complementary mechanisms of reduced energy intake and increased energy expenditure that do not fully overlap.
Phase 3 trials of retatrutide were ongoing as of the time of this review, with completion projected through 2025 and beyond.
Current Research Status
Retatrutide has completed Phase 2 clinical trials in three distinct populations — adults with obesity, adults with type 2 diabetes, and adults with metabolic dysfunction-associated steatotic liver disease — with published results across all three appearing in the New England Journal of Medicine, The Lancet, and Nature Medicine respectively. Phase 3 trials are ongoing as of 2024 and 2025.
Retatrutide has not been approved by the FDA or any regulatory body for any indication as of the time of this post. It remains an investigational compound. Phase 3 trial completion and regulatory review are required before any potential approval pathway could be established. The approval process for a novel compound of this class is typically a multi-year process following Phase 3 completion.
The following remain to be established through Phase 3 data and long-term follow-up studies: long-term cardiovascular outcomes, effects following cessation of treatment and weight regain trajectory, long-term safety beyond the 48-week Phase 2 observation window, and optimal dose escalation protocols for broader populations.
Reconstitution Note
Retatrutide is a peptide compound. Bacteriostatic water is the standard reconstitution solvent for this class of compound in laboratory research settings. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate peptide aggregation, deamidation, and structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Retatrutide product page: